6 results about "Deficiency anemias" patented technology

In an iron (II) citrate monohydrate, identified by the formula FeC6H6O7-H2O ( Ferrous citrate monohydrate or iron citrate (II) monohydrate), obtained according to a particular production method, citric acid and elemental iron are bound in a molecular complex where the iron is agglomerated in the citrate which moves to a cyclic form and the iron is bound to the O groups of the carboxylic groups 1 and 3 through ionic bonds, forming two enantiomers, D and L (R and S), both perfectly water-soluble and highly assimilable by the human body. Formula (L) & Formula (D). With a different absorption mechanism from traditional iron molecules, said iron citrate monohydrate is usable in pharmaceutical and / or nutraceutical and / or food compositions, in particular in the treatment and prevention of iron deficiency anemias and in general of all diseases and disorders associated with iron deficiency. The effectiveness is proven by several examples.

The present invention provides antibodies that bind to BMP6, and methods of use. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to BMP6. The antibodies of the invention are useful for inhibiting binding of BMP6 to the hemojuvelin receptor, thereby down-regulating transcription and expression of hepcidin, thus providing a means of preventing or treating an iron-deficiency anemia or an iron-deficiency related disorder. In some embodiments, the antibodies of the present invention are used in treating at least one symptom or complication of an iron-deficiency anemia or an iron-deficiency related disorder.

The invention discloses application of artesunate in preparation of medicines and health care products for preventing and treating iron-deficiency anemia caused by iron absorption disorder and / or iron transport dysfunction, in-vitro experiments find that artesunate can target divalent metal transport protein (DMT1), DMT1 is oxidized through free radicals to form disulfide bonds, the space structure of DMT1 is changed, and the iron-deficiency anemia caused by iron absorption disorder and / or iron transport dysfunction is prevented. The iron transport function of the DMT1 protein is enhanced, so that the uptake of divalent iron by cells is effectively increased; animal experiments further prove that the artesunate can remarkably improve anemia symptoms of mice with iron-deficiency anemia, anemia related indexes of the mice are effectively recovered, and the iron content in red blood cells and livers is recovered to the normal level. In-vitro and in-vivo experiments prove the treatment effect of artesunate on iron-deficiency anemia, a new treatment scheme is provided for treatment of iron-deficiency anemia patients, and the indication types of artemisinin drugs are expanded.

Complex molecular units of ferrous bis-citrate monot art rate stable over time, which has optimal bioavailability, are obtained through a particular and simple synthesis method, and have the following structural formula M: STRUCTURAL FORMULA M Through a polymerization method, such complex molecular units of iron bis-citrate monotartrate form the monomers of a cyclic polymer structure having the following structural formula P: STRUCTURAL FORMULA P where the iron content per each mole of substance is equal to 50. 20% (w / w), and where the same iron has the dual role of bridging the two acids which move in a cyclic form and binding to the 0- groups of the carboxylic groups by means of dative covalent bonds, resulting in both intramolecular and intermolecular bonds. Such a cyclic polymer structure is usable in pharmaceutical, food, and / or nutraceutical composit ions, in particular in the treatment and prevention of iron deficiency anemias and, in general, all diseases or disorders associated with iron deficiency.

Use of artesunate in the preparation of a medicament for preventing and treating anemia. In vitro experiments have shown that artesunate can enhance the iron transport function of the DMT1 protein to increase iron ion uptake. In addition, animal experiments have demonstrated that artesunate can significantly improve anemia symptoms in mice with iron-deficiency anemia, effectively restore anemia-related indicators, and even restore the iron content in red blood cells and the liver to a healthy level.